Logo

BMS' Opdivo (nivolumab) + Yervoy (ipilimumab) Receive EC's Approval for 1L Treatment for Unresectable Malignant Pleural Mesothelioma

Share this

BMS' Opdivo (nivolumab) + Yervoy (ipilimumab) Receive EC's Approval for 1L Treatment for Unresectable Malignant Pleural Mesothelioma

Shots:

  • The approval is based on P-III CheckMate -743 study assessing Opdivo (3 mg/kg- q2w) + Yervoy (1 mg/kg- q6w) vs CT in patients with previously untreated MPM
  • The trial met its 1EP i.e improvement in OS (26% reduction in risk of death) m-OS (18.1 vs 14.1 mos.)- ORR (40% vs 43%)- DoR (11.0 vs 6.7 mos.)- mPFS (6.8 vs 7.2 mos.). The safety profile of combination treatment was consistent with previous studies in other tumor types
  • The approval allows for use of combination regimens in all 27 member states of EU- Norway- Liechtenstein & Iceland. Additionally- the combination has been approved in 6 countries- including the US & regulatory applications are under review by health authorities

  Ref: BMS | Image: BMS

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions